<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989325</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-520-216</org_study_id>
    <nct_id>NCT01989325</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-520 and Carfilzomib in Patients With Advanced Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study during which patients with advanced multiple myeloma will receive
      either carfilzomib alone (single-agent) or carfilzomib in combination with investigational
      study drug ARRY-520. Patients will be followed to determine the effectiveness of both
      single-agent carfilzomib and carfilzomib + ARRY-520 in treating myeloma. Patients will be
      allowed to crossover from single-agent carfilzomib to carfilzomib + ARRY-520 if disease
      progression occurs. Approximately 75 patients from the US will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of progression-free survival.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of objective response rate.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of both carfilzomib + study drug and single-agent carfilzomib in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of study drug, carfilzomib and a carfilzomib metabolite in patients treated with carfilzomib + study drug in terms of plasma concentration-time profiles and model-based PK parameters.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Following crossover from single-agent carfilzomib, assess the efficacy of carfilzomib + study drug in terms of objective response rate.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Following crossover from single-agent carfilzomib, assess the safety of carfilzomib + study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate patient serum levels of alpha 1-acid glycoprotein (AAG) at Baseline and during the treatment period.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib + ARRY-520</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib, proteasome inhibitor; intravenous</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>Carfilzomib + ARRY-520</arm_group_label>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-520, KSP(Eg5) inhibitor; intravenous</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>Carfilzomib + ARRY-520</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, steroid; oral or intravenous</intervention_name>
    <description>as indicated, per the carfilzomib prescribing information</description>
    <arm_group_label>Carfilzomib + ARRY-520</arm_group_label>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Carfilzomib + ARRY-520</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed multiple myeloma with measurable disease.

          -  Disease refractory to last myeloma regimen.

          -  Patients must have received at least 2 prior treatment regimens, including bortezomib
             and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and
             stem cell transplant Â± maintenance are to be considered as a single regimen.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14
             days prior to first dose of study treatment.

          -  Adequate hematology, liver and renal function laboratory values within 14 days prior
             to first dose of study treatment.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Prior treatment with carfilzomib, ARRY-520, or any other KSP inhibitor.

          -  Past or current plasma cell leukemia.

          -  Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).

          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and
             skin changes).

          -  Ongoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy
             with pain despite appropriate interventions, within 28 days prior to first dose of
             study treatment.

          -  Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to
             first dose of study treatment.

          -  Concomitant malignancies or previous malignancies (other than multiple myeloma) with
             less than a 2-year disease-free interval at the time of first dose of study
             treatment. Patients with adequately resected basal or squamous cell carcinoma of the
             skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are
             eligible irrespective of the time of diagnosis.

          -  Known pulmonary hypertension of any severity.

          -  Concurrent cardiac disease that, in the judgment of the Investigator, would make the
             patient inappropriate for study participation.

          -  Known positive serology for the human immunodeficiency virus (HIV), active hepatitis
             B and/or hepatitis C.

          -  Acute active infection requiring treatment.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Array BioPharma Clinical Trial Call Center</last_name>
    <phone>303-381-6604</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Malone</last_name>
      <phone>310-794-0242</phone>
      <email>rmalone@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Young</last_name>
      <phone>707-521-3814</phone>
      <email>kyoung@rrmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz</last_name>
      <phone>720-848-0628</phone>
      <email>derek.schatz@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lowell Hart, MD</last_name>
      <email>llhart@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Duffey</last_name>
      <email>s-duffey@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University - Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Cangany</last_name>
      <phone>317-274-2178</phone>
      <email>mcangany@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Raje</last_name>
      <phone>617-724-4000</phone>
      <email>nraje@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Davis</last_name>
      <phone>313-576-9370</phone>
      <email>davisv@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura McBride</last_name>
      <phone>551-996-8704</phone>
      <email>lmcbride@hackensackumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikoletta Lendvai, MD, PhD</last_name>
      <phone>212-639-3368</phone>
      <email>lendvain@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tipton</last_name>
      <phone>704-355-6079</phone>
      <email>mary.tipton@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Valent</last_name>
      <phone>216-444-7923</phone>
    </contact>
    <contact_backup>
      <last_name>Cancer Answer Line</last_name>
      <phone>1-800-223-2273</phone>
      <phone_ext>47923</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Stamper</last_name>
      <phone>614-366-6386</phone>
      <email>kathleen.stamper@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Anderson</last_name>
      <phone>503-494-3358</phone>
      <email>andenich@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nan Subbiah</last_name>
      <phone>503-494-4603</phone>
      <email>subbiahn@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Meyer</last_name>
      <email>debra.meyer@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Roberto</last_name>
      <phone>214-648-6554</phone>
      <email>anne.roberto@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Hodge</last_name>
      <email>nicole.hodge@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WVU - Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Beal</last_name>
      <phone>304-293-0609</phone>
      <email>pbeal@hsc.wvu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
